|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Urology |
|
Date of Birth |
1974 |
NARITA Sintaro
|
|
|
Research Interests 【 display / non-display 】
-
泌尿器癌
-
腹腔鏡手術
-
泌尿器腫瘍
-
腹腔鏡手術
-
robotic surgery
Graduating School 【 display / non-display 】
-
-1999.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2004.09
Akita University Graduate School,Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2020.05-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Associate Professor
-
2017.01-2020.04
Akita University Hospital Division of Blood Purification Associate Professor
-
2011.01-2016.12
Akita University Hospital Urology Lecturer
Research Achievements 【 display / non-display 】
-
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Mizuki Kobayashi, Kazuyuki Numakura, Shingo Hatakeyama, Toshiya Ishida, Atsushi Koizumi, Kazuki Tadachi, Ryoma Igarashi, Koichiro Takayama, Yumina Muto, Yuya Sekine, Ryuta Sobu, Hajime Sasagawa, Hideo Akashi, Soki Kashima, Ryohei Yamamoto, Taketoshi Nara, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
International journal of clinical oncology 28 ( 11 ) 1530 - 1537 2023.11
Research paper (journal)
BACKGROUND: Although nivolumab plus ipilimumab is the standard treatment for metastatic renal cell carcinoma (RCC), its efficacy and safety in older patients remain unclear. Therefore, this study aimed to assess the clinical outcomes of nivolumab plus ipilimumab for metastatic RCC in patients aged ≥ 75 years. METHODS: We enrolled 120 patients with metastatic RCC treated with nivolumab plus ipilimumab from August 2015 to January 2023. Objective response rates (ORRs) were compared between patients aged < 75 and ≥ 75 years. Progression-free survival (PFS), overall survival (OS), and adverse events were compared between the groups. Adverse events were evaluated according to the Response Evaluation Criteria in Solid Tumors 1.1. RESULTS: Among the patients, 57 and 63 were classified as intermediate and poor risk, respectively, and one could not be classified. The median follow-up duration after the initiation of treatment was 16 months. The patient characteristics between the groups, except for age, were not significantly different. Intergroup differences in ORR (42% vs. 40%; p = 0.818), PFS (HR: 0.820, 95% CI 0.455-1.479; p = 0.510), and median OS (HR: 1.492, 95% CI 0.737-3.020; p = 0.267) were not significant. The incidence of adverse events (50% vs. 67%; p = 0.111) and nivolumab plus ipilimumab discontinuation due to adverse events was not significantly different between the groups (14% vs. 13%; p = 0.877). CONCLUSIONS: The effectiveness of nivolumab plus ipilimumab was comparable between patients with metastatic RCC aged < 75 and those ≥ 75 years with respect to their ORRs, PFS, OS, and adverse event rates.
-
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.
Kazuyuki Numakura, Mizuki Kobayashi, Yumina Muto, Hiromi Sato, Yuya Sekine, Ryuta Sobu, Yu Aoyama, Yoshiko Takahashi, Syuhei Okada, Hajime Sasagawa, Shintaro Narita, Satoshi Kumagai, Yuki Wada, Naoko Mori, Tomonori Habuchi
Current oncology (Toronto, Ont.) 30 ( 9 ) 8092 - 8110 2023.09
Research paper (journal)
A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures. Prostate brachytherapy is currently considered as a combination therapy. Spacers are useful to protect adjacent organs, specifically the rectum, from excessive radiation exposure.
-
Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata, Satoshi Sato, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
Cancer medicine 12 ( 16 ) 16837 - 16845 2023.08
Research paper (journal)
BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients with mRCC. Therefore, this investigation aimed to evaluate the clinical implication of PRD in patients with mRCC to select better candidates in whom NIVO+IPI can be initiated as first-line therapy. METHODS: This multi-institutional retrospective cohort study used data collected between August 2015 and January 2023. In total, 120 patients with mRCC treated with NIVO+IPI were eligible. Associations between immune-related adverse events and progression-free survival, overall survival (OS), and objective response rate were analyzed. The relationship between other clinical factors and outcomes was also evaluated. RESULTS: The median observation period was 16 months (interquartile range, 5-27). The median age at NIVO+IPI initiation was 68 years in the male-dominant population (n = 86, 71.7%), and most patients had clear cell histology (n = 104, 86.7%). PRD was recorded in 26 (23.4%) of 111 investigated patients during NIVO+IPI therapy. Patients who experienced PRD showed worse OS (hazard ratio: 4.525, 95% confidence interval [CI]: 2.315-8.850, p < 0.001). Multivariable analysis showed that lymph node metastasis (LNM) (odds ratio: 4.274, 95% CI: 1.075-16.949, p = 0.039) was an independent risk factor for PRD. CONCLUSIONS: PRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first-line therapy and might indicate that a candidate will not benefit from NIVO+IPI.
-
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Yoichiro Tohi, Ryou Ishikawa, Takuma Kato, Jimpei Miyakawa, Ryuji Matsumoto, Keiichiro Mori, Koji Mitsuzuka, Junichi Inokuchi, Masafumi Matsumura, Kenichiro Shiga, Hirohito Naito, Yasuo Kohjimoto, Norihiko Kawamura, Masaharu Inoue, Shusuke Akamatsu, Naoki Terada, Yoshiyuki Miyazawa, Shintaro Narita, Reiji Haba, Mikio Sugimoto
Japanese journal of clinical oncology 2023.07
Research paper (journal)
BACKGROUND: In men undergoing upfront active surveillance, predictors of adverse pathology in radical prostatectomy specimens, including intraductal carcinoma of the prostate and cribriform patterns, remain unknown. Therefore, we aimed to examine whether adverse pathology in radical prostatectomy specimens could be predicted using preoperative patient characteristics. METHODS: We re-reviewed available radical prostatectomy specimens from 1035 men prospectively enrolled in the PRIAS-JAPAN cohort between January 2010 and September 2020. We defined adverse pathology on radical prostatectomy specimens as Gleason grade group ≥3, pT stage ≥3, pN positivity or the presence of intraductal carcinoma of the prostate or cribriform patterns. We also examined the predictive factors associated with adverse pathology. RESULTS: All men analyzed had Gleason grade group 1 specimens at active surveillance enrolment. The incidence of adverse pathologies was 48.9% (with intraductal carcinoma of the prostate or cribriform patterns, 33.6%; without them, 15.3%). The addition of intraductal carcinoma of the prostate or cribriform patterns to the definition of adverse pathology increased the incidence by 10.9%. Patients showing adverse pathology with intraductal carcinoma of the prostate or cribriform patterns had lower biochemical recurrence-free survival (log-rank P = 0.0166). Increasing age at active surveillance enrolment and before radical prostatectomy was the only predictive factor for adverse pathology (odds ratio: 1.1, 95% confidence interval: 1.02-1.19, P = 0.0178; odds ratio: 1.12, 95% confidence interval: 1.02-1.22, P = 0.0126). CONCLUSIONS: Increasing age could be a predictive factor for adverse pathology. Our findings suggest that older men could potentially derive advantages from adhering to the examination schedule in active surveillance.
-
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Takafumi Yanagisawa, Kenichi Hata, Shintaro Narita, Shingo Hatakeyama, Keiichiro Mori, Yuji Yata, Takayuki Sano, Takashi Otsuka, Shuhei Hara, Keiichiro Miyajima, Yuki Enei, Wataru Fukuokaya, Minoru Nakazono, Akihiro Matsukawa, Jun Miki, Tomonori Habuchi, Chikara Ohyama, Shahrokh F Shariat, Takahiro Kimura
The Prostate 83 ( 6 ) 563 - 571 2023.05
Research paper (journal)
PURPOSE: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. METHODS: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd- and 3rd-line PFS, were compared. We used one-to-two propensity score matching to minimize the confounders. The differential efficacy of 2nd-line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest. RESULTS: After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3-year OS and CSS for DOC versus ABI were 76.2% versus 75.1% (p = 0.8) and 78.2% versus 78.6% (p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd-line PFS (14 vs. 4 months, p < 0.001) and 3rd-line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd-line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd-line therapy (both 3 months, p = 0.8). CONCLUSIONS: ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd-line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.
-
BRAF V600E変異は副腎腫瘍からのコルチゾール産生を亢進する(BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma)
沼倉 一幸, 武藤 弓奈, 杉山 志子, 小林 瑞貴, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 齋藤 満, 成田 伸太郎, 西本 紘嗣郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 110回 AOP08 - 03 2023.04
-
日本人上部尿路上皮癌の大規模ゲノム解析(Large-scale genetic analysis of Upper Urinary Tract Urothelial Carcinoma in Japanese)
関根 悠哉, 岩崎 雄介, 遠藤 ミキ子, 佐野 剛視, 赤松 秀輔, 小林 恭, 中川 英刀, 沼倉 一幸, 成田 伸太郎, 桃沢 幸秀, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 110回 AOP06 - 07 2023.04
-
転移性腎癌におけるイピリムマブ・ニボルマブ併用療法の早期の耐性化と関連因子の検討
武藤 弓奈, 沼倉 一幸, 畠山 真吾, 関根 悠哉, 小林 瑞貴, 嘉島 相輝, 山本 竜平, 奈良 健平, 齋藤 満, 成田 伸太郎, 大山 力, 羽渕 友則
日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 60回 P51 - 1 2022.10
-
転移性腎細胞癌患者におけるニボルマブ+イピリムマブ療法と免疫関連有害事象との関連
沼倉 一幸, 小林 瑞貴, 武藤 弓奈, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 齋藤 満, 成田 伸太郎, 羽渕 友則
日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 60回 O9 - 2 2022.10
-
細胞質内におけるコネキシン43の発現が腎細胞癌の予後に与える影響(High expression of Connexin 43 in cytoplasm relates to worse clinical outcomes in patients with renal cell carcinoma)
小林 瑞貴, 大森 泰文, 沼倉 一幸, 関根 悠哉, 武藤 弓奈, 成田 伸太郎, 羽渕 友則
日本癌学会総会記事 ( (一社)日本癌学会 ) 81回 P - 3190 2022.09
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Academic Awards Received 【 display / non-display 】
-
Best Presentation Award of the ACRLS 2022
2022.12 Asian-Pacific Congress of Robotic Laparoscopic Surgery Best Presentation Award of the ACRLS 2022
Winner： Shintaro Narita
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2021.04 - 2025.03
-
Establishment of novel therapeutic system for renal cell carcinoma by pahrmacogenomics and transcriptomics
Grant-in-Aid for Scientific Research(C)
Project Year： 2015.04 - 2018.03 Investigator(s): Tsuchiya Norihiko
-
Diet-induced macrophage inhibitory cytokine 1 and prostate cancer progression.
Grant-in-Aid for Scientific Research(C)
Project Year： 2012.04 - 2015.03 Investigator(s): HUANG Mingguo, NARITA Shintaro, TSUCHIYA Norihiko
-
Identification of molecules involved in progression of prostate cancer and construction of risk prediction model using SNP array
Grant-in-Aid for Scientific Research(C)
Project Year： 2012.04 - 2015.03 Investigator(s): TSUCHIYA Norihiko, HABUCHI Tomonori, NARITA Shintaro
-
Molecular Analysis of Rare Renal Cell Carcinoma and Identification of Molecular Therapeutic Targets
Grant-in-Aid for Challenging Exploratory Research
Project Year： 2011 - 2013 Investigator(s): HABUCHI Tomonori, OHYAMA Chikara, MIMATA Hiromitsu, NARITA Shintaro, NANJO Hiroshi